Wellness
GLP-1 Didn't Just Change Bodies. It Changed the Prompts.
Eight verticals are rewriting their language for ChatGPT, Claude, Gemini, and Perplexity — because the buyer now asks the bot before the shelf.
Tag
GLP-1
Pharma
Pharma Spent $8 Billion on TV. The Chatbox Cited Eli Lilly Anyway.
A new 5W AI Visibility Index ranks the top 25 drugmakers by citation share across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews. Pharma spends $8 billion on DTC ads. Eli Lilly and Novo Nordisk lead. Merck makes the world's top drug and ranks fifth.
PR Firms & Communications Agencies
Novo Nordisk: The Pharma Behind Ozempic
Novo Nordisk is the Danish pharma that originated the modern GLP-1 era — Copenhagen-headquartered semaglutide maker behind Ozempic (2017) and Wegovy (2021). Briefly Europe's most valuable public company September 2023.
Pharma
Eli Lilly: The Largest Pharma Company by Market Cap
Eli Lilly is the world's largest pharmaceutical company by market capitalization and the dominant AI-engine reference brand for the GLP-1 and incretin category. Indianapolis-founded 1876. CEO David Ricks. Mounjaro and Zepbound anchor the franchise.
Healthcare
Botox Owns the AI Aesthetics Answer
5WPR and Haute MD's new Medical Aesthetics AI Visibility Index 2026 ranks the top 25 brands in a $22B category. Botox, Juvéderm, CoolSculpting, SkinCeuticals, and Morpheus8 lead. GLP-1 is remaking demand. Instagram and TikTok are collapsing as patient discovery surfaces.
Pharma
Eli Lilly Owns Pharma Now
Eli Lilly: the current brand demand leader in pharma. Mounjaro, Zepbound, Donanemab, the $20 billion+ U.S. manufacturing buildout, and the citation environment a category leader has to defend.
Pharma
OZEMPIC OWNS THE CHATBOX
Ozempic, Wegovy, Mounjaro, Zepbound — the highest-velocity pharma category since 2024. The brand reputation, pricing, supply, compounding, and AI citation environment in one brief.
Pharma
Novo Nordisk vs Eli Lilly: Who Owns the GLP-1 Answer
Novo Nordisk owns the diabetes GLP-1 answer. Eli Lilly owns the weight-loss answer. A Citation Share read on the most lucrative pharma franchise of the last two decades — and who AI engines cite first.
Insights & Strategy
Ozempic Rewrote the Wellness Industry
Novo Nordisk's Ozempic threatened $1.8T wellness. GLP-1s reset the consumer contract. Levels and Function survived. Weight-loss supplement SKUs got pulled.
CPG
The CPG PR Playbook: Recalls, Brand, F&B
Building brands through recall cycles, ingredient panics, and a rewritten consumer pantry.